|Drug harms in the UK: a multicriteria decision analysis|
DJ Nutt, LA King, LD Phillips
The Lancet 376 (9752), 1558-1565, 2010
|Development of a rational scale to assess the harm of drugs of potential misuse|
D Nutt, LA King, W Saulsbury, C Blakemore
the Lancet 369 (9566), 1047-1053, 2007
|Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function|
V Papadopoulos, M Baraldi, TR Guilarte, TB Knudsen, JJ Lacapère, ...
Trends in pharmacological sciences 27 (8), 402-409, 2006
|Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study|
RL Carhart-Harris, M Bolstridge, J Rucker, CMJ Day, D Erritzoe, M Kaelen, ...
The Lancet Psychiatry 3 (7), 619-627, 2016
|Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin|
RL Carhart-Harris, D Erritzoe, T Williams, JM Stone, LJ Reed, A Colasanti, ...
Proceedings of the National Academy of Sciences 109 (6), 2138-2143, 2012
|The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs|
RL Carhart-Harris, R Leech, PJ Hellyer, M Shanahan, A Feilding, ...
Frontiers in human neuroscience, 20, 2014
|Neural correlates of the LSD experience revealed by multimodal neuroimaging|
RL Carhart-Harris, S Muthukumaraswamy, L Roseman, M Kaelen, ...
Proceedings of the National Academy of Sciences 113 (17), 4853-4858, 2016
|Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology|
DS Baldwin, IM Anderson, DJ Nutt, B Bandelow, A Bond, JRT Davidson, ...
Journal of Psychopharmacology 19 (6), 567-596, 2005
|Sleep disorders as core symptoms of depression|
D Nutt, S Wilson, L Paterson
Dialogues in clinical neuroscience, 2022
|Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents|
RD Gibbons, CH Brown, K Hur, SM Marcus, DK Bhaumik, JA Erkens, ...
American Journal of Psychiatry 164 (9), 1356-1363, 2007
|Psilocybin with psychological support for treatment-resistant depression: six-month follow-up|
RL Carhart-Harris, M Bolstridge, CMJ Day, J Rucker, R Watts, DE Erritzoe, ...
Psychopharmacology 235, 399-408, 2018
|Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the …|
DS Baldwin, IM Anderson, DJ Nutt, C Allgulander, B Bandelow, ...
Journal of Psychopharmacology 28 (5), 403-439, 2014
|British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders|
SJ Wilson, DJ Nutt, C Alford, SV Argyropoulos, DS Baldwin, AN Bateson, ...
Journal of psychopharmacology 24 (11), 1577-1601, 2010
|The dopamine theory of addiction: 40 years of highs and lows|
DJ Nutt, A Lingford-Hughes, D Erritzoe, PRA Stokes
Nature Reviews Neuroscience 16 (5), 305-312, 2015
|Amphetamine, past and present–a pharmacological and clinical perspective|
DJ Heal, SL Smith, J Gosden, DJ Nutt
Journal of psychopharmacology 27 (6), 479-496, 2013
|Relationship of neurotransmitters to the symptoms of major depressive disorder|
J Clin psychiatry 69 (Suppl E1), 4-7, 2008
|Homological scaffolds of brain functional networks|
G Petri, P Expert, F Turkheimer, R Carhart-Harris, D Nutt, PJ Hellyer, ...
Journal of The Royal Society Interface 11 (101), 20140873, 2014
|Role of GABA in anxiety and depression|
AV Kalueff, DJ Nutt
Depression and anxiety 24 (7), 495-517, 2007
|Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety|
JC Ballenger, JR Davidson, Y Lecrubier, DJ Nutt, EB Foa, RC Kessler, ...
Journal of clinical psychiatry 61, 60-66, 2000
|Serotonin and brain function: a tale of two receptors|
RL Carhart-Harris, DJ Nutt
Journal of Psychopharmacology 31 (9), 1091-1120, 2017